Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Invesco Ltd.

Invesco Ltd. lowered its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 81.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,732 shares of the company's stock after selling 133,187 shares during the quarter. Invesco Ltd.'s holdings in Kymera Therapeutics were worth $1,236,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of KYMR. Wellington Management Group LLP increased its holdings in Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after buying an additional 688,967 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after buying an additional 133,546 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after acquiring an additional 95,547 shares during the period. Norges Bank bought a new stake in Kymera Therapeutics during the 4th quarter valued at approximately $3,670,000. Finally, Geode Capital Management LLC lifted its holdings in Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after purchasing an additional 52,263 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have commented on KYMR. Stephens reissued an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Citigroup assumed coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target on the stock. Finally, HC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Stock Performance

KYMR stock traded down $1.30 during midday trading on Monday, reaching $33.98. The stock had a trading volume of 274,445 shares, compared to its average volume of 555,444. The firm has a fifty day simple moving average of $29.68 and a two-hundred day simple moving average of $38.12. The stock has a market cap of $2.21 billion, a PE ratio of -14.41 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52-week low of $19.45 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to analysts' expectations of $14.81 million. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is owned by corporate insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.